<DOC>
	<DOCNO>NCT00143390</DOCNO>
	<brief_summary>To verify non-inferiority exemestane compare anastrozole time tumor progression ( TTP ) , primary efficacy endpoint , postmenopausal woman advanced/recurrent breast cancer .</brief_summary>
	<brief_title>Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Have histologically cytologically confirm breast cancer original diagnosis . At study entry , patient must metastatic progressive locally recurrent inoperable breast cancer . Having receive hormonal therapy ( e.g. , Tamoxifen , LHRHagonists ) ovariectomy chemotherapy advanced/recurrent breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
</DOC>